22 completed, 3 terminated, 2 unknown. 14 Phase 2, 9 Phase 1, 4 Not applicable, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 11, Terminated 2, Unknown 1 |
| Phase 1 | 9 | Completed 8, Terminated 1 |
| Not applicable | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Advanced Adult Hepatocellular Carcinoma: new trials by email Literature Review of Advanced Adult Hepatocellular Carcinoma trials Research Report on Advanced Adult Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy Cabozantinib - Advanced Adult Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 3 | 2021-08-06 | 2024-08-06 |
| Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma Hepatocellular Carcinoma, Liver Cancer | Completed | Inonu University | 424 | 2020-06-15 | 2020-10-06 | |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer Magnetic Resonance Elastography, Magnetic Resonance Imaging - Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Not applicable | Completed | M.D. Anderson Cancer Center | 6 | 2019-06-11 | 2025-02-19 |
| Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sorafenib Tosylate - Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 37 | 2017-12-07 | 2026-02-05 |
| An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects AlloVax, AlloStim, CRCL - Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | Mirror Biologics, Inc. | 15 | 2016-07-01 | 2020-01-22 |
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma ENMD-2076 - Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 35 | 2015-10-01 | 2025-04-18 |
| Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Dalantercept plus sorafenib - Advanced Adult Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 21 | 2014-08-04 | 2022-09-26 |
| Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma TACE plus rAd-p53 artery injection, TACE - Advanced Adult Hepatocellular Carcinoma | Phase 2 | Unknown | Shenzhen SiBiono GeneTech Co.,Ltd | 120 | 2014-07-01 | 2015-04-17 |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Chinese herbal formulation PHY906, sorafenib tosylate, laboratory biomarker analysis - Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 1 | Completed | City of Hope Medical Center | 18 | 2014-06-11 | 2021-01-27 |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Capecitabine, Fluorouracil, Laboratory Biomarker Analysis - Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2014-02-01 | 2017-09-12 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Sorafenib Tosylate - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma | Not applicable | Completed | Roswell Park Cancer Institute | 30 | 2013-11-18 | 2022-07-25 |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib - Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2013-09-13 | 2021-12-30 |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery Tivozanib (1mg), Tivozanib (1.5mg) - Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 33 | 2013-07-11 | 2020-10-28 |
| A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma AZD9150 - Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic | Phase 1 | Completed | AstraZeneca | 58 | 2013-05-01 | 2017-03-06 |
| A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC Conventional Transarterial Chemoembolization (cTACE) - Advanced Adult Hepatocellular Carcinoma | Phase 3 | Completed | National Cancer Center, Korea | 339 | 2013-02-21 | 2018-03-29 |
| Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma G-202 - Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | GenSpera, Inc. | 25 | 2013-01-01 | 2016-08-23 |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Everolimus, Pasireotide - Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 24 | 2011-12-01 | 2016-04-07 |
| Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma Best Supportive Care, sorafenib - Advanced Adult Hepatocellular Carcinoma | Phase 3 | Terminated | National Cancer Institute, Naples | 35 | 2011-07-01 | 2017-03-28 |
| Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers DCE MRI - Advanced Adult Hepatocellular Carcinoma | Not applicable | Unknown | Yonsei University | 30 | 2011-04-01 | 2013-06-04 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-04-01 | 2016-06-17 |
Showing 20 of 27. Sign in to see all of them.
Carcinoma, Hepatocellular (18) · Liver Neoplasms (3) · Gallbladder Neoplasms (2) · Bile Duct Neoplasms (1) · Burkitt Lymphoma (1) · Cholangiocarcinoma (1) · Fallopian Tube Neoplasms (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Klatskin Tumor (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Liver Cirrhosis (1)
Adenocarcinoma (18) · Carcinoma (18) · Digestive System Diseases (18) · Digestive System Neoplasms (18) · Liver Diseases (18) · Neoplasms by Histologic Type (18) · Neoplasms by Site (18) · Neoplasms, Glandular and Epithelial (18) · Neoplasms (17) · Liver Neoplasms (15) · Biliary Tract Diseases (2) · Biliary Tract Neoplasms (2) · Gallbladder Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Sorafenib (8) · MK 2206 (2) · ALK1-Fc fusion protein, human (1) · Bevacizumab (1) · Capecitabine (1) · Dasatinib (1) · Disulfides (1) · Doxorubicin (1) · ENMD 2076 (1) · Everolimus (1) · Fluorouracil (1) · Immunoglobulin G (1) · Leucovorin (1) · Magnetic Resonance Imaging (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (7) · Roswell Park Cancer Institute (3) · M.D. Anderson Cancer Center (2) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (1) · AstraZeneca (1) · CASI pharmaceuticals, Inc. (1) · City of Hope Medical Center (1) · GenSpera, Inc. (1) · Inonu University (1) · Mirror Biologics, Inc. (1) · Montefiore Medical Center (1) · National Cancer Center, Korea (1) · National Cancer Institute, Naples (1) · Shenzhen SiBiono GeneTech Co.,Ltd (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (20) · South Korea (3) · Canada (2) · China (1) · Hong Kong (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)
Renuka Iyer (2) · Ahmed O Kaseb (1) · Anthony El-Khoueiry, MD (1) · Antonio Gasbarrini, M.D. (1) · Bruno Daniele, M.D. (1) · Ciro Gallo, M.D., Ph.D (1) · Devalingam Mahalingam, M.D., Ph.D. (1) · Francesco Perrone, M.D., Ph.D (1) · Frank Neumann, MD (1) · Ghassan Abou-Alfa, MD (1) · Ghassan K Abou-Alfa (1) · Giacomo Carteni', M.D. (1) · Gilbert Whang (1) · Hanna Sanoff, MD (1) · Henry Pitot (1)
PMID 25318437, PMID 25488966, PMID 30352941, PMID 30529387, PMID 31391334, PMID 31486832, PMID 32037403, PMID 32154962, PMID 33101775, PMID 33445053, PMID 34071188, PMID 34527608, PMID 35484400, PMID 37702588
N01CM00038 (3), N01CM00070 (2), N01CM00071 (2), U10CA032102 (2), U10CA180888 (2), N01CM00032 (1), N01CM00039 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1)